Format

Send to

Choose Destination
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):631-6.

Ramelteon for insomnia in two youths with autistic disorder.

Author information

1
Department of Psychiatry, Indiana University School of Medicine and the Christian Sarkine Autism Treatment Center at the James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202-5200, USA. kstigler@iupui.edu

Abstract

OBJECTIVE:

The aim of this study was to report preliminary data on the effectiveness and tolerability of ramelteon for the treatment of insomnia in youth with autistic disorder (autism).

METHOD:

Two youths, ages 7 and 18 years, with autism and significant insomnia characterized by problems with sleep onset and maintenance received an open-label trial of ramelteon (4-8 mg) over a duration of 16-18 weeks.

RESULTS:

Target symptoms of delayed sleep onset and/or frequent nocturnal awakening improved significantly, as determined by Clinical Global Impressions-Improvement (CGI-I) scale ratings of either "much improved" or "very much improved." Ramelteon was well tolerated. No daytime sedation was reported.

CONCLUSIONS:

This case report illustrates the potential effectiveness and tolerability of ramelteon for sleep disturbances in 2 patients with autism. Further research is needed to verify its safety, tolerability, and efficacy in children and adolescents with autism.

PMID:
17069551
DOI:
10.1089/cap.2006.16.631
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center